newsfilter
← Latest News
PR Newswire·

Ember LifeSciences announces new strategic investments boosting Series A to $27M

  • Ember LifeSciences announced strategic investments from Amgen Ventures and TDF Ventures.
  • The funding follows a previously announced Series A round led by Sea Court Capital.
  • Total Series A funding for the company now stands at $27 million.
  • Ember Cube 2 is now fully commercially available as a reusable, modular solution for cold chain logistics.
  • The Ember Cube 2 recently received the 'Best of the Best' designation from the Red Dot Award for product design.
  • Existing customers and investors include CVS Health, Cardinal Health, Chartwell, and USADA.
  • The flagship Ember Cube was named a 2024 TIME Magazine Invention of the Year and a 2024 Fast Company World Changing Idea.
  • Ember aims to reduce billions in annual pharmaceutical cold chain losses caused by temperature excursions.
  • Financial terms of the new investments were not disclosed.
  • The company originated from Ember Technologies, known for its temperature control mug with over $500 million in total sales.